

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 August 2007 (16.08.2007)

PCT

(10) International Publication Number
WO 2007/092451 A2

(51) International Patent Classification: Not classified (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TI, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number: PCT/US2007/003160

(22) International Filing Date: 5 February 2007 (05.02.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/765,800 6 February 2006 (06.02.2006) US

(71) Applicant (for all designated States except US): THE BRIGHAM AND WOMEN'S HOSPITAL, INC. [US/US]; 75 Francis Street, Boston, MA 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KASPER, Dennis, L. [US/US]; 48 Monument Avenue, Charlestown, MA 02129 (US). MAZMANIAN, Sarkis, K. [US/US]; 20029 Livorno Way, Porter Ranch, CA 91326 (US).

(74) Agent: STEELE, Alan, W.; Wolf, Greenfield & Sacks, P.c., 600 Atlantic Avenue, Boston, MA 02210 (US).


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ZWITTERIONIC POLYSACCHARIDES FOR PROMOTION OF IMMUNE SYSTEM MATURATION AND HEALTH



(57) Abstract: Certain zwitterionic polysaccharides, including those naturally expressed by commensal *B. fragilis* in the gut, interact with cells of the immune system and affect the T_H1/T_H2 balance so as to promote health. Nutritional formulas and nutritional supplements containing isolated preparations of such zwitterionic polysaccharides, and methods for preparing the nutritional formulas and supplements, are provided. Also provided is a method of promoting immune system maturation in an infant involving enteral administration of a nutritional formula or nutritional supplement of the invention.

WO 2007/092451 A2

- 1 -

ZWITTERIONIC POLYSACCHARIDES FOR PROMOTION OF IMMUNE SYSTEM MATURATION AND HEALTH

BACKGROUND OF THE INVENTION

5 Immediately after a sterile birth, mammals are initiated into an organized and life-long process of colonization by foreign organisms. Shaped by eons of evolution, some host-bacterial associations have developed into prosperous relationships creating diverse environments. No better example exists in biology than the astounding numbers of bacteria harbored by the lower gastrointestinal tract of mammals (Hooper et al., 1998).

10 By young adulthood, humans and other mammals are host to $\sim 10^{12}$ viable bacteria per gram of colonic content, consisting of 500-1000 microbial species and outnumbering host cells by 100-fold (Hooper and Gordon, 2001). The magnitude of this interaction between commensal bacteria and mammals must predictably exert fundamental influences on the physiology of both. The most impressive feature of this relationship

15 may be that the host not only tolerates but has evolved to require colonization by commensal microorganisms for its own development and health.

Autochthonous (indigenous) bacteria in the mammalian gut have long been appreciated for potential benefits to the host: provision of essential nutrients, metabolism of indigestible compounds, defense against colonization by opportunistic pathogens, and contributions to the development of the intestinal architecture (Hooper et al., 2000; Hooper et al., 2002). For some years workers have sought to understand how and why the immunocompetent gut environment allows the presence of multitudinous foreign organisms. Researchers have proposed that certain commensal bacteria have evolved to aid in the host's health; several organisms are being studied for probiotic (beneficial) potential (Guarner and Malagelada, 2003; Rastall, 2004). The "hygiene hypothesis" suggests that the appropriate bacterial constitution of the human microflora is a factor in protection from allergy and asthma (Umetsu et al, 2002; Von Hertzen and Haahtela, 2004). Investigations have shown that the interactions of commensal bacteria with Toll-like receptors are critical for intestinal homeostasis (Rakoff-Nahoum et al., 2004). The intimate relationships between commensal microorganisms and the host immune system are increasingly evident (Macpherson and Harris, 2004; Noverr and Huffnagle, 2004).

The mammalian immune system is a dynamic and remarkable organ. In recognizing, responding, and adapting to countless foreign and self molecules, the

- 2 -

immune system is central to processes of health and disease. CD4⁺ T cells, a major component of the immune system, are required for vital aspects of proper immune function, from reactions to infectious agents to control of autoimmune reactions and cancers (Janeway et al., 2001). Effector CD4⁺ T cells are of two general subtypes: T helper 1 (T_H1) and T helper 2 (T_H2), each carrying out distinct and opposing activities. The proper balance between T_H1 and T_H2 immunologic responses is critical to overall human and animal health (Neurath et al., 2002; Sheikh and Strachan, 2004). A role for commensal bacteria in establishing this equilibrium has been postulated (Bowman and Holt, 2001; Rook and Brunet, 2002).

10 *Bacteroides fragilis* (*B. fragilis*) is a ubiquitous and important gram-negative anaerobe that colonizes the mammalian lower gastrointestinal tract. *Bacteroides spp.* are among the earliest-colonizing and most numerically prominent constituents of the gut microflora (Kononen et al., 1992). Although capsular polysaccharides are common in many bacterial species, *B. fragilis* elaborates an unprecedented eight distinct surface 15 polysaccharides (Krinos et al., 2001). Several of these polysaccharides have a characteristic zwitterionic structure, with both positive and negative charges in each repeating unit (Tzianabos et al., 1993):

20 Zwitterionic polysaccharides (ZPSs) are unique T cell-dependent antigens that specifically mediate the proliferation of CD4⁺ T cells *in vitro* (Brubaker et al., 1999; Tzianabos and Kasper, 2002). Adoptive transfer experiments have shown that responses to polysaccharide A (PSA), the most immunodominant ZPS of *B. fragilis*, are conferred by CD4⁺ T cells, not by B cells or other T cells (Tzianabos et al., 1999). PSA is internalized and processed within endosomes of antigen-presenting cells (APCs) (Cobb et al., 2004). Subsequent presentation of processed polysaccharide by major 25 histocompatibility complex class II (MHC II) molecules activates CD4⁺ T cells and represents a previously undescribed pathway of antigen presentation. Thus ZPSs appear to have evolved novel biological activities shaped by co-evolution with the host immune system.

30

SUMMARY OF THE INVENTION

The invention is based in part on the discovery by the applicants that enteral administration of a zwitterionic polysaccharide, such as the bacterial capsular

- 3 -

polysaccharide PSA isolated from *B. fragiils*, can influence overall immune homeostasis through the zwitterionic polysaccharide's ability to mediate establishment of a proper T_{H1}/T_{H2} balance for the host, a fundamental aspect of healthy immunologic function.

More particularly, according to the invention ZPSs can be included in nutritional

5 formulas and nutritional supplements and administered to a subject to help promote and maintain a desirable balance between T_{H1} and T_{H2} throughout the immune system.

Establishment of a proper T_{H1}/T_{H2} balance using the compositions and methods of the invention promotes a state of health characterized by diminished risk of having or developing a number of immune-mediated conditions associated with a default T_{H2}

10 phenotype, e.g., atopy (allergy predisposition), allergic asthma, and autoimmunity.

Compositions and methods of the invention are thus useful whenever it is desirable to provide a T_{H1} stimulus to the immune system of a mammalian subject. In particular, the compositions and methods of the invention are useful in stimulating a proper T_{H1}/T_{H2} balance in human infants and other human subjects that have an immature immune

15 system or predisposition to develop a default T_{H2} phenotype.

In one aspect the invention is a nutritional formula or nutritional supplement composition, comprising an isolated zwitterionic polysaccharide consisting essentially of repeating units, wherein each repeating unit comprises two to ten monosaccharides and a positively charged free amino moiety and a negatively charged moiety selected from the 20 group consisting of carboxylate, phosphate, phosphonate, sulfate, and sulfonate.

In one aspect the invention is a method for preparing a nutritional formula or nutritional supplement composition. The method according to this aspect of the

invention includes the step of combining an isolated zwitterionic polysaccharide, said polysaccharide consisting essentially of repeating units, wherein each repeating unit

25 comprises two to ten monosaccharides and a positively charged free amino moiety and a negatively charged moiety selected from the group consisting of carboxylate, phosphate, phosphonate, sulfate, and sulfonate, with a nutritional formula or nutritional supplement that is otherwise free of the isolated zwitterionic polysaccharide.

In one aspect the invention is a method of promoting immune system maturation

30 in an infant. The method according to this aspect of the invention includes the step of enterally administering to the infant an effective amount of a nutritional formula or nutritional supplement composition, said composition comprising an isolated

- 4 -

zwitterionic polysaccharide consisting essentially of repeating units, wherein each repeating unit comprises two to ten monosaccharides and a positively charged free amino moiety and a negatively charged moiety selected from the group consisting of carboxylate, phosphate, phosphonate, sulfate, and sulfonate.

5 In one embodiment the zwitterionic polysaccharide is a naturally occurring bacterial capsular polysaccharide.

In one embodiment the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide A (PSA). In one embodiment the PSA is PSA1.

In one embodiment the PSA is PSA2.

10 In one embodiment the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide B (PSB).

In one embodiment the zwitterionic polysaccharide is selected from the group consisting of *Shigella sonnei* Phase I lipopolysaccharide O-antigen, *Streptococcus pneumoniae* type 1 capsular polysaccharide, and *Streptococcus pneumoniae* group antigen C substance.

15 In one embodiment the nutritional formula or nutritional supplement is a nutritional formula.

In one embodiment the nutritional formula or nutritional supplement is a nutritional supplement.

20 In one embodiment the enteral administering is orally administering.

In one embodiment the infant is 0-6 months old.

In one embodiment the immune system maturation is an increase in a T helper 1 marker to a T helper 2 marker.

25 In one embodiment the T helper 1 marker is a cytokine selected from interferon gamma (IFN- γ) and interleukin 2 (IL-2).

In one embodiment the T helper 2 marker is a cytokine selected from interleukin 4 (IL-4) and interleukin 5 (IL-5).

BRIEF DESCRIPTION OF THE DRAWINGS

30 Figure 1. Cellular and Physical Immune Maturation in Germ-Free Mice Requires PSA Production During Intestinal *B. fragilis* Colonization.

(A) Flow cytometry (FC) analysis of anti-CD4-stained splenic lymphocytes from

- 5 -

conventionally colonized (CNV) and germ-free (GF) mice reveals depletion of CD4⁺ T cells in the absence of colonizing microflora in the gastrointestinal (GI) tract. Results are representative of 4 experiments with pools of 3-5 mice.

(B) Quantitation of fecal colony forming units (CFU) during mono-colonization of GF mice with wild-type *B. fragilis* or an isogenic mutant deficient in PSA production (*B. fragilis* ΔPSA) reveals equivalent counts of viable bacteria from fecal pellets. Inset: Immunoblot of bacterial extracts with anti-PSA after SDS-PAGE separation and electro-transfer to PVDF membranes shows the lack of PSA expression by *B. fragilis* ΔPSA.

(C) FC of anti-CD4-stained splenic lymphocytes from GF mice shows that intestinal mono-colonization of mice with *B. fragilis* results in complementation of CD4⁺ T cells. In the presence of every other antigen produced during colonization with *B. fragilis* ΔPSA, the absence of PSA results in no increase in CD4⁺ T cell counts. Results are representative of >10 experiments with single or pools of 3-5 mice.

(D) FC of splenic lymphocytes from CNV and GF mice colonized with wild-type or *B. fragilis* ΔPSA reveals no significant differences in CD19⁺ B cells (upper panels) or CD8⁺ T cells (lower panels) in the CD4⁻ fraction. Results are representative of 4 experiments with pools of 3-5 mice.

(E) Hematoxylin and eosin (H&E) stained sections of spleens from CNV mice (right), GF mice mono-colonized with wild-type *B. fragilis* (left) and with *B. fragilis* ΔPSA (center). White pulp containing lymphocytes appears as darker-staining follicular structures (arrows). The lack of large, well-defined follicles in mice colonized with *B. fragilis* ΔPSA is a measure of T cell depletion and reflects developmental defects in organogenesis. All images were taken at the same magnification.

Figure 2. Purified PSA Treatment Is Sufficient for Expansion of CD4⁺ T Cells.

(A) FC of anti-CD4-stained splenic lymphocytes from GF mice treated intraperitoneally with PSA or phosphate buffered saline (PBS) reveals PSA-dependent restoration of CD4⁺ T cells. Results are representative of 2 experiments with pools of 4 mice.

(B) FC shows that oral treatment of conventional C57BL/6 and BALB/c mice with purified PSA (PSA) results in an increase in CD4⁺ T cell proportion among splenic lymphocytes over controls (PBS). Results are representative of 4 experiments with pools

- 6 -

of 3-5 mice.

(C) FC shows that oral treatment of conventional mice with purified PSA does not affect proportions of CD8⁺ T cells or CD19⁺ B cells among the CD4⁻ splenic lymphocyte population.

5

Figure 3. PSA Is Specifically Recognized by Dendritic Cells (DCs) in the GI Tract and in Vitro, with Consequent Cell Activation.

(A) Oral treatment of mice with Alexa-594-labeled PSA results in antigen uptake by CD11c⁺ DCs from mesenteric lymph nodes (MLNs). FC of CD11c⁺ gated cells

10 (boxed left panel, middle) analyzed for the presence of PSA (horizontal axis of right panels) shows co-localization of PSA with DCs. FC of isolated MLNs reveals no PSA associated with CD4⁺ T cells from the same lymph nodes (boxed left panel, bottom). Isotype control is shown in the top left panel. Shaded histograms represent unstained control, and thick black lines denote Alexa-594 signal from PSA on the horizontal axis.

15 No PSA is detectable in splenic tissues (data not shown).

(B) Confocal microscopy of anti-CD11c-labeled (originally green) and 24-hour PSA-treated (originally red) bone marrow-derived dendritic cells (BMDCs) in culture illustrate antigen in endosomes and surface display (arrowheads). Central image is the XY-plane of a medial Z-section, upper and side panels are assembled Z-stacks.

20 (C) FC of BMDCs cultured for 24 hours with PSA shows activation by up-regulation of MHC II (horizontal axis) among CD11c⁺ cells (vertical axis).

(D) FC of CD11c⁺ BMDCs cultured for 24 hours with PSA shows activation through up-regulation of the co-stimulatory molecule CD86 (B7.2).

25 Figure 4. PSA Induces CD4⁺ T Cell Proliferation and T_H1 Cytokine Production in Vitro.

(A) CD4⁺ T-cell proliferation by [³H]thymidine incorporation increases in response to irradiated BMDCs (1x10⁶) incubated with PSA. Treatment of co-cultures with NAc-PSA results in no increase in cell proliferation. Lipopolysaccharide (LPS) treatment or DCs or T cells alone do not support CD4⁺ T-cell proliferation. Results are representative of 3 experiments.

- 7 -

(B) PSA treatment stimulates IFN- γ in DC-T cell co-cultures, as measured by enzyme-linked immunosorbent assay (ELISA) of culture supernatants after 48 hours of treatment. NAc-PSA treatment has no effect. Treatment with anti-CD3, LPS, and staphylococcal enterotoxin A (SEA), all known stimulators of T_H1 cytokine expression, 5 results in IFN- γ production. DCs or T cells alone treated with PSA do not support cytokine expression.

(C) PSA treatment does not stimulate expression of IL-4 in DC-T cell co-cultures. Treatment with anti-CD3 and SEA, known stimulators of T_H2 cytokine expression, results in IL-4 production.

10

Figure 5. PSA Signals Through the IL-12/Stat4 Pathway to Mediate T_H1 Cytokine Production, Which Requires Presentation by MHC II.

(A) PSA stimulates expression of IL-12, the T_H1 determining signal, in DC-T cell co-cultures (1×10^6 of each cell type). NAc-PSA treatment has no effect. Anti-CD3 and 15 SEA serve as controls for IL-12 expression by BMDCs. Results are representative of 2 experiments.

(B) IL-12 is required for PSA-mediated IFN- γ production. IFN- γ expression is abolished in DC-T cell co-cultures treated with PSA (100 μ g/mL) in the presence neutralizing antibody to IL-12. Neutralization of IL-12 does not inhibit anti-CD3- 20 mediated IFN- γ expression, which is IL-12 independent.

(C) PSA signals through Stat4 to induce IFN- γ secretion by T cells. IFN- γ expression from DC-T cell co-cultures treated with PSA (100 μ g/mL) is reduced when CD4 $^+$ T cells are purified from spleens of *stat4* knockout rather than wild-type mice (Figure 4B).

(D) MHC class II expressed on DCs is necessary for PSA-mediated IFN- γ expression by CD4 $^+$ T cells. IFN- γ production by DC-T cell co-cultures treated with PSA (100 μ g/mL) is reduced when BMDCs are from MHC II knockout mice. NAc-PSA (100 μ g/mL) treatment of wild-type DCs (MHC II $^{+/+}$) serves as the control for PSA-specific IFN- γ expression.

25

Figure 6. Colonization of GF Mice with PSA-Producing *B. fragilis* Corrects T_H1/T_H2 Imbalances Associated with Cytokine-Mediated Pathologies.

- 8 -

(A) IL-4 production from splenic CD4⁺ T cells stimulated *in vitro* with anti-CD3/anti-CD28 (2 µg/mL each), reveals that PSA is required to correct the T_H2 skew in GF mice. Compared with CNV mice, GF mice overproduce IL-4 (first and second bars). Intestinal colonization with *B. fragilis* (third bar) reduces the expression of IL-4 from 5 levels in GF mice. *B. fragilis* ΔPSA colonization fails to correct the T_H2 skew (fourth bar). Results are representative of 2 experiments from pools of 4 mice.

(B) IFN-γ expression by splenic CD4⁺ T during colonization indicates increased T_H1 cytokine production in CNV than in GF mice (first and second bars). PSA 10 production by intestinal *B. fragilis* is required for the increase in IFN-γ expression and immune homeostasis (third bar); homeostasis is not seen in the absence of PSA (fourth bar).

(C) Intracellular cytokine staining and FC of *in vitro* stimulated (500 ng/mL PMA, 5 µg/mL ionomycin) cultures of splenic CD4⁺ T cells for 4 hours in the presence of brefeldin A shows that IFN-γ (horizontal axis) is produced specifically by CD4⁺ T 15 cells (vertical axis) during bacterial colonization. PSA production by *B. fragilis* is required for the specific increase in IFN-γ expression to levels similar to those for CNV mice. GF and *B. fragilis* ΔPSA-colonized mice express low levels of T_H1 cytokines. Results are representative of 3 experiments with pools of 3-5 mice.

(D) Thymic histology of germ-free mice (H&E) colonized with wild-type or *B. fragilis* ΔPSA for over 1 year reveal follicles (arrows) within the inner medullary 20 compartment in the absence of PSA. None of 5 *B. fragilis*-colonized compared to 3 of 5 *B. fragilis* ΔPSA-colonized mice displayed follicles.

(E) FC of thymic tissues recovered from groups of differentially colonized GF mice (10 per group) reveals the anomalous presence of CD19⁺ B cells in *B. fragilis* 25 ΔPSA-colonized mice, a condition likely resulting from increased T_H2 cytokine production in the absence of PSA.

DETAILED DESCRIPTION OF THE INVENTION

It has now been found that maturation of the mammalian immune system is 30 profoundly influenced by the specific direction of an immunomodulatory molecule expressed by the symbiotic bacteria, *B. fragilis*. This organism, a ubiquitous constituent

of the mammalian lower gastrointestinal microflora, elaborates a zwitterionic polysaccharide (i.e., PSA) that directs the development of CD4+ T cells; the eventual result is the correction of immunologic defects found in the absence of bacterial colonization. Impaired systemic CD4+ T cell maturation, aberrant $T_{H}1/T_{H}2$ lineage differentiation, and defective lymphoid organ development can all be corrected by PSA or by PSA production during *B. fragilis* colonization. Dendritic cells in gut-associated lymphoid tissues (GALT) apparently sample *B. fragilis* and/or PSA from the intestine and after activation migrate to lymphoid organs and signal $T_{H}1$ lineage differentiation through the IL-12/STAT4 pathway. As $T_{H}1$ cytokine production opposes the $T_{H}2$ default phenotype, this process contributes to protection from disease by creating appropriate cytokine balances in the immune system.

It has been hypothesized that reduced exposure to immunomodulatory molecules of beneficial commensal bacteria that provide protection from unrelated immune diseases results from improved sanitation and antibiotic use. This "hygiene hypothesis" posits that deviations in gut microflora composition may be the environmental factor underlying development of atopy and asthma in genetically predisposed individuals.

It has now been discovered according to the invention that feeding of PSA or other zwitterionic polysaccharides having the charge characteristics of PSA to newborn infants would provide the appropriate $T_{H}1$ stimulus to their immune systems that would stimulate the infant to develop with a favorable $T_{H}1/T_{H}2$ balance. As described in greater detail below, the feeding of the polysaccharide can be accomplished through enteral administration of infant formulas, nutritional supplements, pills, or liquid suspensions, wherein these agents contain the isolated zwitterionic polysaccharide. In practice this can be done daily at a dose sufficient to maintain $T_{H}1$ stimulation over the course of the first six months to one year of life, allowing full development of a competent and healthy immune system.

Also as described in greater detail below, the polysaccharides can be PSA, PSB, or other zwitterionic polysaccharides characterized by repeating units, each repeating unit bearing a charge motif. In one embodiment, such as in PSA, the charge motif includes one positive charge and one negative charge on each repeating unit. In other embodiments, the charge motif includes at least one positive charge and at least one negative charge on each repeating unit. The positive charge is in the form of a free

- 10 -

amino group and the negative charge is in the form of a carboxylate group, a phosphate group, or other similarly negatively charged residues.

The molecular size of the molecule to be fed could be as small as one or two saccharide units. Recent studies by the inventors have shown that a disaccharide comprised of only one non-acetylated amino sugar and one uronic acid is sufficient to stimulate T-cell proliferation. This is important because it suggests that the natural hydrolysis of these molecules which might take place in the acidic environment of the stomach would still allow carbohydrate molecules to be absorbed that remain active on the immune system.

10 A nutritional formula as used herein refers to a nutritional formulation suitable for enteral administration. Nutritional formulas are well known in the art and are sometimes referred to as enteral formulas. Such preparations typically include a water-based formulation containing a source of nutritional carbohydrate, amino acids and proteins, fat, vitamins, minerals, and optionally other components such as nucleic acids.

15 In one embodiment a nutritional formula refers to an infant formula suitable for administration to human infants. The nutritional formula can be formulated and presented either as a liquid or as a dry powder for reconstitution. A nutritional formula of the invention further specifically includes at least one zwitterionic polysaccharide useful for promoting immune system maturation, as disclosed herein.

20 A nutritional supplement as used herein refers to a composition suitable for enteral administration either as a supplement or as an additive to any one or more components of a diet. A nutritional supplement generally can include at least one source of any one or combination of nutritional carbohydrates, amino acids and proteins, fats, vitamins, minerals, and optionally other components such as nucleic acids. In certain 25 embodiments the nutritional supplement can be formulated and presented as a liquid, as a dry powder, as a capsule, or as a pill. Other formulations are also contemplated, including bars, sprinkles, cereals, gels, pastes, and the like. A nutritional supplement of the invention further specifically includes at least one zwitterionic polysaccharide useful for promoting immune system maturation, as disclosed herein.

30 A zwitterionic polysaccharide as used herein in one embodiment refers to a naturally occurring polysaccharide having certain structural features including the presence of repeating units, each with at least one positively charged moiety and at least

one negatively charged moiety. A zwitterionic polysaccharide as used herein in one embodiment refers to polysaccharides that have been modified to include the structural features including the presence of repeating units, each with at least one positively charged moiety and at least one negatively charged moiety. The zwitterionic 5 polysaccharides useful according to the invention generally have a plurality of repeating units, wherein each repeating unit comprises two to ten monosaccharides and a positively charged free amino moiety and a negatively charged moiety selected from the group consisting of carboxylate, phosphate, phosphonate, sulfate, and sulfonate. Molecular 10 weights of the zwitterionic polysaccharides useful in the invention typically have molecular weights between 500 Da and 2,000,000 Da, although smaller and larger polysaccharides can also be used. For example, the polysaccharide can be as small as one or two saccharide units. Thus a disaccharide including only one non-acetylated amino sugar and one uronic acid is sufficient to stimulate T-cell proliferation.

15 Polysaccharides useful according to the present invention include those naturally occurring polysaccharides that include the requisite charged groups. These polysaccharides may be derived from bacterial sources. Bacteria used as starting materials to obtain capsular polysaccharides can be obtained commercially from a number of sources. For example, the *B. fragilis*, NCTC 9343 and ATCC 23745 may be obtained from the National Collection of Type Cultures (London, England) and the 20 American Type Culture Collection (Manassas, Md.). Polysaccharide A and polysaccharide B can be purified from the above bacteria following the protocol of Pantosti et al. (1991) *Infect Immun* 59:2075-2082.

25 In addition to the naturally occurring polysaccharides, polysaccharide repeating units that consist of at least one N-acetyl sugar and at least one uronic acid (sugar with a negatively charged carboxyl group) can be modified to produce the immune response of the present invention. A polysaccharide repeating unit containing at least one N-acetyl sugar and at least one uronic acid can be de-N-acetylated to create a free amino group and thus will yield a polysaccharide with the correct charge motif. Molecules which may be de-N-acetylated include *Salmonella typhi* capsular polysaccharide (VI antigen), 30 *Escherichia coli* K5 capsular polysaccharide, *Staphylococcus aureus* type 5 capsular polysaccharide, Group B *Streptococcus* type III capsular polysaccharide, and *Rhizobium meliloti* exopolysaccharide II. These polysaccharides and their modification have been

described in U.S. Pat. No. 5,679,654, the entire contents of which is incorporated herein by reference.

De-N-acetylation can be accomplished by conventional chemistry techniques well known to those of ordinary skill in the art. One suitable method involves the use of 5 alkali with or without sodium borohydride. Twenty mg of polysaccharide is dissolved in 2M NaOH (3 ml) and sodium borohydride is added (50 mg). The solution is heated to 100°C for 5 h. Following neutralization with acid, the solution is dialyzed against distilled water in the cold and freeze-dried. DiFabio, J. L., Michon, F., Brisson, J. R., Jennings, H. J., Weasels, M. R. Benedi, V. J., Kasper, D. L. (1989) Structure of the 10 capsular polysaccharide antigen of type IV groups B Streptococcus. *Can J Chem* 67:877-882.

Bacterial polysaccharides which possess imine groups (C=NH) in addition to free carboxyl groups may be modified and used to produce the immune response of the present invention. Many of the *Pseudomonis aeruginosa* O-specific side chains possess 15 imine groups. Imine groups can be reduced with sodium borohydride (NaBH₄) to create free amino groups (NH₃⁺). An example of a compound which may be reduced with sodium borohydride to create free amino groups is *Pseudomonas aeruginosa* Fisher 7.

A bacterial capsular polysaccharide as used herein refers to a polysaccharide which occurs in nature as a component of the capsule of a bacterial cell. For use in the 20 present invention, a bacterial capsular polysaccharide is isolated from the bacterial cell in which it occurs in nature. As used herein, isolated means removed from other components with which a polysaccharide may be found in nature.

A naturally occurring bacterial capsular polysaccharide as used herein refers to a bacterial capsular polysaccharide that is not modified from how it occurs in nature except 25 for being isolated.

B. fragilis polysaccharide A (PSA) as used herein refers to *B. fragilis* capsular polysaccharide A as disclosed, for example, in U.S. Pat. No. 5,679,654. This polysaccharide has a tetrasaccharide repeating unit containing one cationic free amine and one anionic carboxylate in each repeating unit. Tzianabos AO et al. (1992) *J Biol Chem* 267:18230-5.; U.S. Pat. Nos. 5,679,654 and 5,700,787. PSA is also known as 30 PSA1.

- 13 -

PSA2 as used herein refers to *B. fragilis* capsular polysaccharide A as disclosed, for example, in Wang Y et al. (2000) *Proc Natl Acad Sci USA* 97:13478-83, and Kalka-Moll WM et al. (2001) *Infect Immun* 69:2339-44. *Bacteroides fragilis* PSA2 has a pentasaccharide repeating unit containing mannoheptose, N-acetylmannosamine, 3-acetamido-3,6-dideoxyglucose, 2-amino-4-acetamido-2,4,6-trideoxygalactose, fucose, and 3-hydroxybutanoic acid. PSA2 is zwitterionic and carries one cationic free amine and one anionic carboxylate in each repeating unit.

B. fragilis polysaccharide B (PSB) as used herein refers to *B. fragilis* capsular polysaccharide B as disclosed, for example, in U.S. Pat. No. 5,679,654. This polysaccharide has a repeating unit that includes six monosaccharides.

Shigella sonnei Phase I lipopolysaccharide O-antigen, *Streptococcus pneumoniae* type 1 capsular polysaccharide, and *Streptococcus pneumoniae* group antigen C substance are additional zwitterionic polysaccharides disclosed for example in U.S. Pat. No. 5,679,654 and useful in the instant invention.

Immune system maturation as used herein refers to development of an immune system characterized by a T_{H1}/T_{H2} balance that is associated with a healthy adult phenotype. A healthy adult phenotype is to be contrasted with a default T_{H2} phenotype that is characteristic of atopy, allergic asthma, or certain types of autoimmune disease. Immune system maturation can be assessed by measuring, either at a single point in time or serially over a relevant span of time, relative contributions of at least one T_{H1} marker and at least one T_{H2} marker.

An infant as used herein refers to a human less than 12 months old. In one embodiment an infant is 0-9 months old. In one embodiment an infant is 0-6 months old. In one embodiment an infant is 0-3 months old.

As used herein, enterally has its usual meaning and refers to any route involving administration to at least one component of a gastrointestinal tract. Enteral administration can be accomplished by any suitable method, including oral feeding (e.g., sucking, chewing, swallowing); nasogastric delivery; orogastric delivery; gastric delivery; duodenal, jejunal, or other small intestinal delivery; enema and other forms of delivery to the large intestine. In one embodiment enterally refers to orally.

A T helper 1 marker (T_{H1} marker) as used herein refers to an objectively measurable manifestation of a T_{H1} immune phenotype. T_{H1} markers include, without

- 14 -

limitation, certain cytokines including interferon gamma (IFN- γ) and interleukin 2 (IL-2), as well as certain immunoglobulin isotypes, e.g., IgG1 in humans and IgG2a in mice. Methods for measuring T_{H1} cytokines and immunoglobulin isotypes are well known in the art and can include, without limitation, appropriate cytokine-specific or isotype-specific enzyme-lined immunosorbent assay (ELISA), bioassay, quantitative reverse transcriptase-polymerase chain reaction, and the like.

5 A T helper 2 marker (T_{H2} marker) as used herein refers to an objectively measurable manifestation of a T_{H2} immune phenotype. T_{H2} markers include, without limitation, certain cytokines including interleukin 4 (IL-4) and interleukin 5 (IL-5), as 10 well as certain immunoglobulin isotypes, e.g., IgE in humans and in mice. Methods for measuring T_{H2} cytokines and immunoglobulin isotypes are well known in the art and can include, without limitation, appropriate cytokine-specific or isotype-specific ELISA, bioassay, quantitative reverse transcriptase-polymerase chain reaction, and the like.

15 An increase in a T helper 1 marker to a T helper 2 marker as used herein refers to skewing a T helper subtype predominance toward a T_{H1} phenotype and/or away from a T_{H2} -dominant phenotype, e.g., away from a T_{H2} default phenotype. Any increase in the ratio of T_{H1} to T_{H2} results in an increase in a T helper 1 marker to a T helper 2 marker. In one embodiment such increase can be measured at a single point in time, with 20 reference made to some standard or control. Alternatively or in addition, in one embodiment such increase can be measured serially over a relevant span of time, comparing results from one time point to results from another time point, for a single subject. Methods for measuring T_{H1} markers and T_{H2} markers are as described above.

25 The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting. The entire contents of all of the references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

30

EXAMPLES

Experimental Procedures

Mice and Bacterial Strains

Conventional specific pathogen-free (SPF) mice of strains C57BL/6NTac, BALB/cAnNTac, B6.SJL-*Ptprc^a*/BoAiTac-H2-*Ab1^{tm1GLM}* N13 (MHCII^{-/-}), and B6.SJL-*Ptprc^a*/BoAiTac (MHCII^{-/-} control) were purchased from Taconic Farms (Germantown, NY). C.129S2-*Stat4^{tm1Gru}* (*Stat4^{-/-}*) mice were purchased from Jackson Laboratory (Bar Harbor, ME). These mice were housed in conventional cages at Harvard Medical School (HMS). Germ-free Swiss-Webster mice were from Taconic Farms and housed in sterile isolators (Class Biologically Clean, Madison, WI). Mice were screened weekly for bacterial, viral, and fungal contamination. All procedures with mice were performed according to guidelines of the HMS Office for Research Subject Protection.

B. fragilis strain NCTC 9343 and its isogenic PSA deletion mutant have been described (Coyne et al., 2001). For mouse colonization, ~1x10⁸ CFU of bacteria grown in BHI medium were spread on food and bedding. Mice were colonized for at least 60 days before examination. Results are for mice up to 8 months post-colonization (except thymic pathology, which requires aging over 1 year).

Lymphocyte Isolation from Tissues

Lymphocytes were isolated from tissues (Tzianabos et al, 2000). In brief, spleens, thymuses, and MLNs were disrupted into single-cell preparations, and enriched for lymphocytes over a Histopaque 1083 gradient (Sigma, St. Louis). Cells were washed with PBS and used directly or fixed with 0.5% PFA for 1 hour at 4°C.

Flow Cytometry, Fluorescence-Activated Cell Sorting and Intracellular Cytokine Staining

Directly fluorochrome-conjugated monoclonal antibodies were used (BD Pharmingen, San Diego). For surface staining, lymphocyte preparations were washed twice in FC buffer (PBS with 2% FBS) and resuspended in 100 µL. 1x10⁶ cells were incubated with antibodies at 2 µg/mL for 30 min at 4°C. For intracellular cytokine staining, cells were resuspended in 100 µL of Cytofix/Cytoperm buffer for 30 min at 4°C, washed with Perm/Wash buffer, and incubated with fluorochrome-conjugated anti-cytokine antibodies for 30 min at 4°C. Cells were washed and analyzed on a model FC500 Cytometer (Beckman Coulter, Fullerton, CA), and all data were analyzed with

- 16 -

RXP Analysis Software (Beckman Coulter). FACS was performed on a BD FACSAria, and cell purity was always >99%.

PSA Purification and Animal Treatment

5 PSA from *B. fragilis* NCTC 9343 was prepared as previously described (Tzianabos et al, 1992). For some studies, PSA was treated with acetic anhydride to neutralize the positively charged amino group (Tzianabos et al., 1994). Mice received 50 µg of PSA in 1.5% sodium bicarbonate/PBS intraperitoneally or intragastrically 3 times a week for 2 weeks. Rag2^{-/-} mice received 30 µg of PSA (PBS controls) in alternating 10 intragastric and subcutaneous treatments 3 times a week.

In Vitro Cytokine Stimulation and Proliferation Assays

For analysis of splenic cytokines, lymphocytes were isolated as above. CD4⁺ T cells were purified with the MACS CD4 Sorting Kit (Miltenyi Biotec, Auburn, CA).

15 Cell purity was >97% CD4⁺. The remaining lymphocytes were used as APCs after gamma-irradiation. 3x10⁵ cells of each type were mixed in a 48-well plate, and anti-CD3/anti-CD28 (2 µg/mL) was added. Supernatants recovered after stimulation for 48 and 72 hours were analyzed by ELISA.

20 For co-cultures, CD4⁺ T cells were purified from splenic lymphocytes with a CD4⁺ T Cell Subset Kit (R&D Systems). Cell purity was >95%. BMDCs from femurs of mice were purified. Cells were cultured for 8 days in C-RPMI-10 with GM-CSF (20 ng/mL; Biosource, Camarillo, CA). Cells were >90% CD11c⁺. 1x10⁶ purified CD4⁺ T cells were mixed with 1x10⁶ purified CD11c⁺ BMDCs and incubated at 37°C / 5% CO₂.

25 ELISA plates were from precoated kits (Biosource). T-cell proliferation assays were done with 1x10⁵ cells of each type (APCs irradiated) after incubation for 96 hours. For the last 8 hours before harvest, wells were pulsed with [³H]thymidine (1 µCi/well). Cells were washed, harvested and counted by liquid scintillation (Wallac; now PerkinElmer, Boston). Data were expressed as mean cpm ± SD for triplicate wells.

30 Histological Tissue Analysis

Paraffin-embedded mouse tissues were stained with H&E. Sections were

- 17 -

evaluated in blinded fashion by a single pathologist (R.T. Bronson, HMS).

Example 1

5 **Mono-Colonization of Germ-Free Animals with *B. fragilis* Results in CD4⁺ T Cell Expansion**

The effects of bacterial colonization on immune maturation in animals were investigated, exploring the role of the microbial flora in systemic T cell development. Germ-free mice, animals born and raised in sterile isolators devoid of microbes, were 10 used. Initially, spleens were harvested from both conventionally colonized and germ-free mice and were analyzed for total CD4⁺ T cells by flow cytometry (FC). All groups of mice had similar splenic total lymphocyte counts (average: 1x10⁸). Consistent with seminal observations of a positive immunologic role of autochthonous bacteria (Dobber et al., 1992), the lymphocyte population purified from spleens of conventional SPF 15 (specific pathogen-free) mice with a diverse gut microflora contained a greater proportion of CD4⁺ T cells than that of germ-free mice (FIG. 1A). Previous studies have documented the beneficial role of commensal bacteria in intestinal development (Hooper, 2004). The observed alteration in CD4⁺ T cell proportions of splenic lymphocytes highlights the profound effects of bacterial colonization of the gut on the 20 systemic immune response.

SPF mice harbor a diverse and complex microbial flora. To stringently investigate the influence of specific bacterial constituents of the gut flora on the host immune system, germ-free mice were colonized with a single bacterial species. This approach allows “real-time” measurements of responses to bacterial colonization in 25 animals with a naïve immune system. The model microorganism *B. fragilis* was chosen because of its prominence in the normal microbial gut flora and its production of known immunomodulatory molecules (Kononen et al., 1992; Tzianabos and Kasper, 2002). In the absence of competing bacterial species, germ-free mice mono-associated with *B. fragilis* strain NCTC 9343 were readily colonized to high levels (>10¹⁰ CFU/g of feces; 30 FIG. 1B). Flow cytometry of splenic lymphocytes from these mice showed a nearly complete restoration of CD4⁺ T cells to conventional proportions (FIG. 1A and FIG. 1C). Thus *B. fragilis* mono-colonization was sufficient to correct CD4⁺ T cell deficiency

- 18 -

in spleens of germ-free mice. No other bacterial species alone has been shown to correct lymphoid defects in germ-free animals (Cash and Hooper, 2005).

Example 2

5 **Immunomodulatory Effects of *B. fragilis* Require Production of PSA**
At least 2 of the 8 capsular polysaccharides of *B. fragilis* are ZPSs, a unique class of bacterial molecules with immunomodulatory properties (Tzianabos and Kasper, 2002). We wondered whether PSA, the most immunodominant and highly conserved ZPS, plays a role in splenic T cell expansion during *B. fragilis* commensalism. PSA-
10 deficient *B. fragilis* Δ PSA were used to mono-colonize germ-free mice (Coyne et al., 2001). The level of intestinal colonization by the mutant was indistinguishable from that by the isogenic parent strain, as assessed by fecal CFU counts (FIG. 1B). Examination of splenic lymphocyte populations from mice colonized with *B. fragilis* lacking PSA but expressing all other antigens produced by this organism revealed an inability to correct
15 CD4 $^{+}$ T-cell deficiencies in germ-free mice (FIG. 1C). In pooled experiments ($n = 4$), the average proportions of CD4 $^{+}$ T cells were: Conventional: 17.82% \pm 2.1; *B. fragilis*: 18.05% \pm 1.9; *B. fragilis* Δ PSA: 10.95% \pm 2.3; and Germ-free: 11.15% \pm 1.5. The effects were specific to CD4 $^{+}$ T cells, as the proportions of CD8 $^{+}$ T cells and CD19 $^{+}$ B cells from splenic lymphocytes (FIG. 1D) were indistinguishable between conventional
20 and either mono-colonized or germ-free mice, as previously observed (Pereira et al., 1986). Together, these results show that *B. fragilis* colonizing the gut of germ-free mice requires PSA production to correct host systemic CD4 $^{+}$ T cell deficiencies during commensalism.

Example 3

PSA Production by *B. fragilis* Directs Lymphoid Organogenesis

Commensal bacteria have long been appreciated for their positive impact on development of gut-associated lymphoid tissues (GALT, including Peyer's patches) and intraepithelial lymphocytes (IELs) and production of mucosal IgA (Hooper, 2004). The 30 experiments in this example examined whether cellular immune maturation after bacterial colonization was also manifested in the morphological and ultrastructural development of peripheral lymphoid tissues. Germ-free animals have recently been

- 19 -

reported to display defects in splenic structural development (Macpherson and Harris, 2004). Histological sections of spleens from germ-free mice colonized with wild-type *B. fragilis* or *B. fragilis* Δ PSA were examined. Spleens from mice mono-colonized with *B. fragilis* appeared normal, with well-formed lymphocyte zones appearing as defined 5 follicles (*white pulp*) similar to those in conventional mice with a complete gut flora (FIG. 1E). The interspersed red pulp was densely packed with red blood cells and neutrophils. Spleens from germ-free mice colonized with *B. fragilis* Δ PSA showed gross anatomical depletion of the lymphocyte zones similar to that in uncolonized germ-free mice (Macpherson and Harris, 2004). Follicles were smaller, less defined, and more 10 fragmented than in germ-free mice colonized with wild-type *B. fragilis* or conventional mice (FIG. 1E). The overall size and shape of spleens from all groups were comparable. This finding suggests a role for PSA specifically in lymphocyte development. Thus changes in CD4 $^{+}$ T cell expansion that are mediated by PSA produced by intestinal bacteria are consistent with the correction of physical and developmental defects in 15 secondary lymphoid tissues. This observation reflects the importance of the beneficial relationship between commensal microorganisms and host physiology.

Example 4

Purified PSA Is Sufficient to Expand T Cells in Germ-Free and Conventional 20 Animals

The inability of a PSA-deficient mutant to cause T-cell expansion showed that the activity of this immunomodulatory molecule is required during *B. fragilis* colonization. Using chromatography to purify PSA extracted from the surface of *B. fragilis*, it was investigated whether PSA alone is sufficient to counter the CD4 $^{+}$ T cell 25 defects in germ-free mice. Purity was assessed by various methods, including H 1 -NMR, spectroscopy, and gel electrophoresis. The preparation was devoid of contamination by protein, nucleic acid, and endotoxin (LPS). Uncolonized germ-free mice were treated intraperitoneally with purified PSA and then assessed for splenic T cell expansion. Purified PSA was found to restore CD4 $^{+}$ T cell proportions among splenic lymphocytes 30 in germ-free mice to conventional levels (FIG. 2A).

To assess whether the route of administration to mice of various backgrounds affects PSA's immunomodulatory properties, both conventionally colonized C57BL/6

- 20 -

and BALB/c mice received purified PSA intragastrically. This treatment recapitulates intestinal exposure of animals to PSA during colonization. Oral treatment led to a specific increase of splenic CD4⁺ T cells in conventional mice (FIG. 2B), showing that PSA's effect is not exclusive to germ-free animals. CD8⁺ T cell and CD19⁺ B cell ratios were unaffected by PSA (FIG. 2C) as formerly shown (FIG. 1D). These studies demonstrated that specific recognition of purified PSA by host immune components in the intestines resulted in splenic CD4⁺ T cell expansion.

In further experiments germ-free mice are administered purified PSA intragastrically. Effects of oral treatment of germ-free mice is assessed by measurement of splenic CD4⁺ T cells, CD8⁺ T cell and CD19⁺ B cell ratios, and T_H1 (e.g., IFN- γ) and T_H2 (e.g., IL-4) cytokine production.

Example 5

PSA Is Specifically Recognized by Dendritic Cells, with Consequent Cell Activation

All CD4⁺ T cell reactions require instruction to T cells by APCs (Kidd, 2003; Kapsenberg, 2003). PSA is recognized by APCs and then presented to T cells *in vitro* (Kalka-Moll et al., 2002). The cellular mechanism of PSA recognition in the intestine and subsequent signaling to expand splenic T cells is unknown. To characterize the APC responsible for PSA effects in animals, mice were fed fluorescently labeled PSA by gavage and then cells were recovered from mesenteric lymph nodes (MLNs). As shown by flow cytometry, PSA specifically associated with CD11c⁺ dendritic cells (DCs; FIG. 3A), and not with CD4⁺ T cells or CD19⁺ B cells (FIG. 3A and data not shown) in the MLNs. The notion of *in vivo* DC recognition of PSA appears appropriate, as DCs are the only APCs known to sample luminal contents from the intestine and migrate to lymph nodes to initiate T cell reactions (Rescigno et al., 2001; Mowat, 2003). Consistent with this hypothesis, no PSA was recovered from spleens of orally treated mice despite splenic T cell expansion. In addition, confocal microscopy revealed that PSA was internalized by primary cultured bone marrow-derived DCs (BMDCs) and was subsequently displayed on the cell surface (FIG. 3B). Thus it appears that DCs sample intestinal PSA by antigen uptake and migrate only as far as the local lymph nodes. These results agree with those of Macpherson and Uhr (2004), who observed that commensal bacteria are internalized by intestinal DCs that migrate to MLNs only.

- 21 -

We next assessed whether the association of PSA with BMDCs leads to cell activation and maturation, as only mature DCs can activate T cells. PSA-mediated maturation of DCs was measured by up-regulation of MHC II among CD11c⁺ cells from 22% to 43% after PSA treatment (FIG. 3C), a process required for efficient antigen display to the receptor on CD4⁺ T cells (Banchereau and Steinman, 1998; Thery and Amigorena, 2001). Treatment also increased expression of the costimulatory molecules CD80 (B7.1) and CD86 (B7.2) in a dose-dependent manner (data not shown and FIG. 3D, respectively), a result further showing that PSA interacts with and induces maturation of DCs. These findings are consistent with the observation that DCs, not B cells, mediate intestinal antigen presentation to T cells after conventionalization of germ-free animals (Yamanaka et al., 2003).

Example 6

PSA Induces T-Cell Proliferation When Presented by DCs in Vitro

To further investigate cellular and molecular events underlying immune responses to PSA, an *in vitro* co-culture system using primary cells to assess the ability of purified PSA to induce T-cell proliferation and cytokine expression was developed. As shown above, PSA treatment led to CD4⁺ T cell expansion in mice. Incubation of PSA with CD11c⁺ BMDCs and naïve splenic CD4⁺ T cells led to a dose-dependent increase in T-cell proliferation (FIG. 4A). Neutralization of the positive charge by chemical modification of PSA (N-acetylated [NAc] PSA) resulted in no incorporation of [³H]thymidine—a marker for cell replication. This extends to DCs our observation that the zwitterionic structure of PSA is critical for biological activity (Kalka-Moll et al., 2002; Tzianabos and Kasper, 2002). Purified *E. coli* LPS did not induce T-cell proliferation in mice (FIG. 4A; LPS). PSA-mediated CD4⁺ T-cell proliferation required both DCs and T cells; either cell type alone resulted in no incorporation of radiolabel (FIG. 4A). Together, these results show that DCs can direct T-cell proliferation in response to purified PSA *in vitro*.

Example 7

PSA Induces T Cell Cytokine Production in Dendritic Cell Co-cultures

- 22 -

The two subtypes of effector CD4⁺ T cells, T_H1 and T_H2, are defined by expression of the cytokines interferon γ (IFN- γ) and interleukin 4 (IL-4), respectively (Janeway et al., 2001). As shown above, PSA induces CD4⁺ T cell expansion in *B. fragilis*-colonized mice and *in vitro*. To further characterize the effects of PSA-mediated 5 T cell activation, cytokine profiles using purified cellular components were assessed. Co-culture of DCs and CD4⁺ T cells in the presence of PSA yielded dose-dependent up-expression of the T_H1 cytokine IFN- γ (FIG. 4B). The level of IFN- γ production associated with PSA was comparable to that associated with several known potent 10 IFN γ inducers (anti-CD3, LPS, and staphylococcal enterotoxin A [SEA]) and required both DCs and T cells (FIG. 4B). Specificity was evidenced by the lack of T_H1 cytokine 15 production after NAc-PSA treatment (FIG. 4B).

T_H1 cytokine production suppresses T_H2 responses; conversely, T_H2 cytokine expression inhibits T_H1 responses. Normal immune responses require a controlled balance of these opposing signals. Examination of IL-4 expression in response to PSA 20 treatment revealed no cytokine production by purified CD4⁺ T cells (FIG. 4C; 100 μ g/ml PSA). Anti-CD3 and the superantigen SEA are potent stimulators of both classes of cytokine (FIG. 4C). As T_H2 cytokine production is a “default pathway” in many systems (Kidd, 2003; Amsen et al. 2004) and T_H1 cytokine production is antagonistic to T_H2 expression, the specific stimulation of IFN- γ by PSA *in vitro* may provide a 25 mechanism for establishing commensal-mediated homeostasis of the host immune system by balancing T_H1/T_H2 responses.

Example 8

T_H1 Cytokine Production in Response to PSA Treatment Requires Signaling

25 Through the IL-12/Stat4 Pathway and MHC II Expression

A unique immunologic molecule, PSA is the only carbohydrate studied to date that is internalized into APCs and displayed by MHC II to T cells (Cobb et al., 2004)—a process previously believed to be reserved for protein antigens. We further characterized the molecular pathway for PSA-induced T_H1 cytokine production. Many of the 30 molecular signaling events involving T-helper cytokine expression are well characterized. The major pathway of IFN- γ up-regulation and T_H1 cell differentiation involves DC secretion of IL-12, which binds to the IL-12 receptor on T cells and signals

- 23 -

to activate the T_{H1} -specific transcription factor Stat4 (Trinchieri, 2003). PSA stimulation of DC-T cell co-cultures elicited a dose-dependent increase in IL-12 production (FIG. 5A). DCs alone stimulated with PSA secreted IL-12 (FIG. 5A, DC 100 μ g/ml PSA), although at levels lower than those found for CD4 $^{+}$ T cells. This is the, 5 first bacterial polysaccharide shown to signal IL-12 secretion by APCs, as previously shown for classical protein antigens (Macatonia et al., 1995). NAc-PSA, lacking the essential positive-charge motif, did not stimulate cytokine production. To determine whether IL-12 is required for T_{H1} cell differentiation, IFN- γ expression was measured after PSA treatment in the presence of increasing concentrations of neutralizing antibody 10 to IL-12 (Heufler et al, 1996). IL-12 neutralization abolished PSA-mediated IFN- γ secretion by CD4 $^{+}$ T cells *in vitro* (FIG. 5B). Ablation of IL-12 signaling does not affect anti-CD3-mediated IFN- γ expression, as this signal is APC-independent, acting directly on T cells. To determine whether IL-12 signaling that results in T_{H1} lineage 15 differentiation involves the Stat4 transcription factor, DCs from wild-type mice were incubated with CD4 $^{+}$ T cells from *stat4* knockout mice and IFN- γ expression in response to PSA treatment was measured. The absence of Stat4 greatly reduced T_{H1} cytokine production (FIG. 5C); thus PSA specifically induced DCs to signal T cell differentiation through Stat4 transcriptional regulation.

To investigate whether antigen presentation of PSA was required for cytokine 20 signaling, DCs were purified from MHC II-deficient mice and DC-T cell co-cultures were treated with PSA or NAc-PSA. The level of IFN- γ expression was significantly higher in wild-type (MHC II $^{+/+}$) mice treated with PSA than in MHC II knockout mice (MHC II $^{-/-}$), which expressed amounts similar to a NAc-PSA control (FIG. 5D). Together, these results demonstrate that T_{H1} cytokine responses to PSA require MHC II 25 expression by APCs and involve signaling through the IL-12/Stat4 pathway to induce T cell activation and proper cytokine expression.

Example 9

PSA Is Required for Appropriate CD4 $^{+}$ T-Helper Cytokine Production during 30 Colonization

A proper T_{H1}/T_{H2} balance is critical for human and animal health; over- or underproduction of either response is associated with immunologic disorders. The

- 24 -

effects of PSA on T_{H1}/T_{H2} cytokine responses in colonized animals were investigated, again using germ-free mice. $CD4^+$ T cells from mouse spleens were purified and tested by ELISA for cytokine production. **FIG. 6A** shows overproduction of the T_{H2} cytokine IL-4 in spleens of germ-free mice compared with levels in conventional mice. This 5 result is consistent with previous reports of the appreciably T_{H2} -skewed profile of mice devoid of bacterial contamination and reflects the human neonatal (precolonization) cytokine profile (Kirjavainen and Gibson, 1999; Prescott et al., 1998; Adkins, 2000; Kidd, 2003). This “default” T_{H2} -bias in the absence of bacterial colonization again highlights the profound contributions of the microflora to immune development and 10 provides a model to test the effects of symbiotic bacteria on the establishment of appropriate host cytokine production.

Mice colonized with wild-type *B. fragilis* alone displayed a level of IL-4 production similar to that in conventional mice with a complex microflora (**FIG. 6A**); this similarity shows the organism’s sufficiency to correct systemic immune defects. 15 Moreover, mice colonized with *B. fragilis* Δ PSA produced T_{H2} cytokines at elevated levels, similar to those in germ-free mice (**FIG. 6A**). Thus the expression of a single bacterial antigen allows *B. fragilis* to correct the IL-4 cytokine imbalance found in uncolonized animals.

Examination of IFN- γ production by purified splenic $CD4^+$ T cells revealed that 20 germ-free mice, which are T_{H2} -skewed, were deficient in production of this prototypical T_{H1} marker when compared to conventional mice (**FIG. 6B**). Colonization with wild-type *B. fragilis* alone was sufficient to correct the defect in IFN- γ expression in germ-free mice, with levels nearly as high as those in conventional mice (**FIG. 6B**). Lack of PSA production by the *B. fragilis* mutant during colonization of germ-free mice resulted in 25 low-level production of T_{H1} cytokines (**FIG. 6B**). These results were corroborated by intracellular cytokine staining of splenic lymphocytes from each group, which confirmed that IFN- γ production was attributable to $CD4^+$ T cells (**FIG. 6C**). The production of IL-2, another T_{H1} cytokine, by $CD4^+$ T cells in gnotobiotic mice also required PSA production (data not shown). Together, these results demonstrate that intestinal 30 colonization of germ-free mice by *B. fragilis* alone was sufficient to establish a proper systemic T_{H1}/T_{H2} balance within the host — a fundamental aspect of the mammalian immune response.

- 25 -

Example 10

Absence of PSA Production by *B. fragilis* During Colonization Is Associated with TH2-Mediated Pathologies of the Thymus

Throughout these studies, specimens obtained at necropsy were subjected to histological examination. A rare pathology of the thymus exclusively in mice colonized with *B. fragilis* Δ PSA was noticed. Thymic tissues from germ-free mice colonized with wild-type *B. fragilis* appeared normal, with a darker-staining outer corona and a uniform and homogeneous inner medullary compartment. Surprisingly, at >1 year of age, the majority of mice colonized with *B. fragilis* Δ PSA displayed the outgrowth of B cell-like follicles in the thymic medulla (FIG. 6D). Flow cytometry showed that these tissues contained CD19⁺ B cells (FIG. 6E) not found in the normal thymus. This rare condition appeared to be similar to human thymic hyperplasia, in which B cells are found in follicles of the medulla (Kasper et al., 2005). The latter condition is associated with numerous autoimmune disorders, most notably myasthenia gravis, a B cell-mediated pathology (Malhotra et al., 1992; Infante and Kraig, 1999). These disorders, as well as B-cell outgrowths, are mediated by overproduction of TH2 cytokines by CD4⁺ T cells (Zhang et al., 1997; Janeway et al., 2001). It is compelling to speculate that the inability to restore proper TH1/TH2 balance in germ-free mice through appropriate commensal colonization results in an aberrant TH2 response, which may lead to immune-mediated pathologies.

REFERENCES

Adkins, B. (2000). Development of neonatal Th1/Th2 function. *Int Rev Immunol* 19, 25 157-171.

Amsen, D., Blander, J. M., Lee, G. R., Tanigaki, K., Honjo, T., and Flavell, R. A. (2004). Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. *Cell* 117, 515-526.

Banchereau, J. and Steinman, R. M. (1998). Dendritic cells and the control of immunity. 30 *Nature* 392, 245-252.

- 26 -

Bowman, L. M., and Holt, P. G. (2001). Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. *Infect Immun* 69, 3719-3727.

Brubaker, J. O., Li, Q., Tzianabos, A. O., Kasper, D. L., and Finberg, R. W. (1999).
5 Mitogenic activity of purified capsular polysaccharide A from *Bacteroides fragilis*: differential stimulatory effect on mouse and rat lymphocytes in vitro. *J Immunol* 162, 2235-2242.

Cash, H. L., and Hooper, L. V. (2005). Commensal bacteria shape intestinal immune system development. *ASM News* 71, 77-83.

10 Cobb, B. A., Wang, Q., Tzianabos, A. O., and Kasper, D. L. (2004). Polysaccharide processing and presentation by the MHCII pathway. *Cell* 117, 677-687.

Coyne, M. J., Tzianabos, A. O., Mallory, B. C., Carey, V. J., Kasper, D. L., and Comstock, L. E. (2001). Polysaccharide biosynthesis locus required for virulence of *Bacteroides fragilis*. *Infect Immun* 69, 4342-4350.

15 Dobber, R., Hertogh-Huijbregts, A., Rozing, J., Bottomly K., and Negelkerken, L. (1992). The involvement of intestinal microflora in the expansion of CD4+ T cells with a naïve phenotype in the periphery. *Dev Immunol* 2, 141-150.

Guarner, F., and Malagelada, J. R. (2003). Gut flora in health and disease. *Lancet* 361, 512-519.

20 Heufler, C., Koch, F., Stanzl, U., Topar, G., Wysocka, M., Trinchieri, G., Enk, A., Steinman, R. M., Romani, N., and Schuler, G. (1996). Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. *Eur J Immunol* 26, 659-668.

Hooper, L. V., Bry, L., Falk, P. G., and Gordon, J. I. (1998). Host-microbial symbiosis in
25 the mammalian intestine: exploring an internal ecosystem. *Bioessays* 20, 336-343.

Hooper, L. V., Falk, P. G., and Gordon, J. I. (2000). Analyzing the molecular foundations of commensalism in the mouse intestine. *Curr Opin Microbiol* 3, 79-85.

30 Hooper, L. V., and Gordon, J. I. (2001). Commensal host-bacterial relationships in the gut. *Science* 292, 1115-1118.

- 27 -

Hooper, L. V., Midtvedt, T., and Gordon, J. I. (2002). How host-microbial interactions shape the nutrient environment of the mammalian intestine. *Annu Rev Nutr* 22, 283-307.

Hooper, L. V. (2004). Bacterial contributions to mammalian gut development. *Trends Microbiol* 12, 129-134.

Infante, A. J. and Kraig, E. (1999). Myasthenia gravis and its animal model: T cell receptor expression in an antibody mediated autoimmune disease. *Int Rev Immunol* 18, 83-109.

Janeway, C.A., Travers, P., Walport, M., and Shlomchik, M. (2001). *Immunobiology* (Garland Publishing).

Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, and Kasper D. L. (2002). Zwitterionic polysaccharides stimulate T cells by MHC class II-dependent interactions. *J Immunol* 169, 6149-53.

Kapsenberg, M. L. (2003). Dendritic-cell control of pathogen-driven T-cell polarization. *Nat Rev Immunol* 3, 984-993.

Kasper, D.L., Braunwald, E., Fauci, A.S., Hauser, S. L., Longo, D. L., and Jameson, J.L. (2005). *Harrison's Principles of Internal Medicine* (McGraw-Hill Publishing).

Kidd, P. (2003). Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. *Altern Med Rev* 8, 223-246.

Kirjavainen, P. V., and Gibson, G. R. (1999). Healthy gut microflora and allergy: factors influencing development of the microbiota. *Ann Med* 31, 288-292.

Kohm, A. P., Carpentier, P. A., Anger, H. A., and Miller, S. D. (2002). Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. *J Immunol* 169, 4712-4716.

Kononen, E., Jousimies-Somer, H., and Asikainen, S. (1992). Relationship between oral gram-negative anaerobic bacteria in saliva of the mother and the colonization of her edentulous infant. *Oral Microbiol Immunol* 7, 273-276.

Krinos, C. M., Coyne, M. J., Weinacht, K. G., Tzianabos, A. O., Kasper, D. L., and Comstock, L. E. (2001). Extensive surface diversity of a commensal microorganism by multiple DNA inversions. *Nature* 414, 555-558.

- 28 -

Macatonia, S. E., Hosken, N. A., Litton, M., Vieira, P., Hsieh, C. S., Culpepper, J. A., Wysocka, M., Trinchieri, G., Murphy, K. M., and O'Garra, A. (1995). Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. *J Immunol* 154, 5071-5079.

5 Macpherson, A. J., and Harris, N. L. (2004). Interactions between commensal intestinal bacteria and the immune system. *Nat Rev Immunol* 4, 478-485.

Macpherson, A. J., and Uhr, T. (2004). Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. *Science* 303, 1662-1665.

10 Malhotra, V., Tatke, M., Khanna, S. K., and Gondal, R. (1992). Thymic histology in myasthenia gravis. *Indian J Chest Dis Allied Sci* 34, 117-121.

Mowat, A. M. (2003). Anatomical basis of tolerance and immunity to intestinal antigens. *Nat Rev Immunol* 3, 331-341.

Neurath, M. F., Finotto, S., and Glimcher, L. H. (2002). The role of Th1/Th2 polarization in mucosal immunity. *Nat Med* 8, 567-573.

15 Noverr, M. C. and Huffnagle, G. B. (2004). Does the microbiota regulate immune responses outside the gut? *Trends Microbiol* 12, 562-568.

Pereira, P., Forni, L., Larsson, E., Cooper, M., Heusser, C., and Coutinho, A. (1986). Autonomous activation of B and T cells in antigen-free mice. *Eur J Immunol* 16, 685-688.

20 Prescott, S. L., Macaubas, C., Holt, B. J., Smallacombe, T. B., Loh, R., Sly, P. D., and Holt, P. G. (1998). Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T cell responses toward the Th2 cytokine profile. *J Immunol* 160, 4730-4737.

Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., and Medzhitov, R. 25 (2004). Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell* 118, 229-241.

Rastall, R. A. (2004). Bacteria in the gut: friends and foes and how to alter the balance. *J Nutr* 134, 2022S-2026S.

30 Rescigno, M., Rotta, G., Valzasina, B., and Ricciardi-Castagnoli, P. (2001). Dendritic cells shuttle microbes across gut epithelial monolayers. *Immunobiology* 204, 572-581.

- 29 -

Rook, G. A., and Brunet, L. R. (2002). Give us this day our daily germs. *Biologist (London)* 49, 145-149.

Sheikh, A., and Strachan, D. P. (2004). The hygiene theory: fact or fiction? *Curr Opin Otolaryngol Head Neck Surg* 12, 232-236.

5 Thery, C., and Amigorena, S. (2001). The cell biology of antigen presentation in dendritic cells. *Curr Opin Immunol* 13, 45-51.

Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. *Nat Rev Immunol* 3, 133-146.

10 Tzianabos, A.O., Pantosti, A., Baumann, H., Brisson, J.R., Jennings, H.J., and Kasper, D.L. (1992). The capsular polysaccharide of *Bacteroides fragilis* comprises two ionically linked polysaccharides. *Biol Chem* 267, 18230-5.

Tzianabos, A. O., Onderdonk, A. B., Rosner, B., Cisneros, R. L., and Kasper, D. L. (1993). Structural features of polysaccharides that induce intra-abdominal abscesses. *Science* 262, 416-419.

15 Tzianabos, A. O., Onderdonk, A. B., Zaleznik, D. F., Smith, R. S., and Kasper, D. L. (1994). Structural characteristics of polysaccharides that induce protection against intra-abdominal abscess formation. *Infect Immun* 62, 4881-4886.

Tzianabos, A. O., Russell, P. R., Onderdonk, A. B., Gibson, F. C., 3rd, Cywes, C., Chan, M., Finberg, R. W., and Kasper, D. L. (1999). IL-2 mediates protection against 20 abscess formation in an experimental model of sepsis. *J Immunol* 163, 893-897.

Tzianabos, A.O., Finberg, R.W., Wang, Y., Chan, M., Onderdonk, A.B., Jennings, H.J., and Kasper, D.L. (2000). T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. *J Biol Chem* 275, 6733-40.

Tzianabos, A. O., and Kasper, D. L. (2002). Role of T cells in abscess formation. *Curr 25 Opin Microbiol* 5, 92-96.

Umetsu, D. T., McIntire, J. J., Akbari, O., Macaubas, C., and DeKruyff, R. H. (2002). Asthma: an epidemic of dysregulated immunity. *Nat Immunol* 3, 715-720.

Von Hertzen, L. C., and Haahtela, T. (2004). Asthma and atopy - the price of affluence? *Allergy* 59, 124-137.

30 Yamanaka, T., Helgeland, L., Farstad, I.N., Fukushima, H., Midtvedt, T., and Brandtzaeg, P. (2003). Microbial colonization drives lymphocyte accumulation

- 30 -

and differentiation in the follicle-associated epithelium of Peyer's patches. *J Immunol.* 170, 816-22.

Zhang, G. X., Navikas, V., and Link, H. (1997). Cytokines and the pathogenesis of myasthenia gravis. *Muscle Nerve* 20, 543-551.

5

EQUIVALENTS

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

We claim:

- 31 -

CLAIMS

1. A nutritional formula or nutritional supplement composition, comprising an isolated zwitterionic polysaccharide consisting essentially of repeating units, wherein
5 each repeating unit comprises

two to ten monosaccharides, and

a free amino moiety and a negatively charged moiety selected from the group consisting of carboxylate, phosphate, phosphonate, sulfate, and sulfonate.

10 2. The composition of claim 1, wherein the zwitterionic polysaccharide is a naturally occurring bacterial capsular polysaccharide.

3. The composition of claim 1, wherein the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide A (PSA).

15 4. The composition of claim 3, wherein the PSA is PSA1.

5. The composition of claim 3, wherein the PSA is PSA2.

20 6. The composition of claim 1, wherein the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide B (PSB).

7. The composition of claim 1, wherein the zwitterionic polysaccharide is selected from the group consisting of *Shigella sonnei* Phase I lipopolysaccharide O-antigen,

25 *Streptococcus pneumoniae* type 1 capsular polysaccharide, and *Streptococcus pneumoniae* group antigen C substance.

8. The composition of claim 1, wherein the nutritional formula or nutritional supplement is a nutritional formula.

30 9. The composition of claim 1, wherein the nutritional formula or nutritional supplement is a nutritional supplement.

10. A method for preparing a nutritional formula or nutritional supplement composition, comprising
 - 5 combining an isolated zwitterionic polysaccharide consisting essentially of repeating units, wherein each repeating unit comprises
 - two to ten monosaccharides, and
 - a free amino moiety and a negatively charged moiety selected from the group consisting of carboxylate, phosphate, phosphonate, sulfate, and sulfonate,
 - 10 with a nutritional formula or nutritional supplement that is otherwise free of the isolated zwitterionic polysaccharide.
11. The method of claim 10, wherein the zwitterionic polysaccharide is a naturally occurring bacterial capsular polysaccharide.
- 15 12. The method of claim 10, wherein the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide A (PSA).
13. The method of claim 12, wherein the PSA is PSA1.
- 20 14. The method of claim 12, wherein the PSA is PSA2.
15. The method of claim 10, wherein the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide B (PSB).
- 25 16. The method of claim 10, wherein the zwitterionic polysaccharide is selected from the group consisting of *Shigella sonnei* Phase I lipopolysaccharide O-antigen, *Streptococcus pneumoniae* type 1 capsular polysaccharide, and *Streptococcus pneumoniae* group antigen C substance.
- 30 17. The method of claim 10, wherein the nutritional formula or nutritional supplement is a nutritional formula.

- 33 -

18. The method of claim 10, wherein the nutritional formula or nutritional supplement is a nutritional supplement.

19. A method of promoting immune system maturation in an infant, comprising
5 enterally administering to the infant an effective amount of a nutritional formula or nutritional supplement composition, said composition comprising an isolated zwitterionic polysaccharide consisting essentially of repeating units, wherein each repeating unit comprises

two to ten monosaccharides, and

10 a free amino moiety and a negatively charged moiety selected from the group consisting of carboxylate, phosphate, phosphonate, sulfate, and sulfonate.

20. The method of claim 19, wherein the zwitterionic polysaccharide is a naturally occurring bacterial capsular polysaccharide.

15 21. The method of claim 19, wherein the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide A (PSA).

22. The method of claim 21, wherein the PSA is PSA1.

20 23. The method of claim 21, wherein the PSA is PSA2.

24. The method of claim 19, wherein the zwitterionic polysaccharide is a *B. fragilis* capsular polysaccharide B (PSB).

25 25. The method of claim 19, wherein the zwitterionic polysaccharide is selected from the group consisting of *Shigella sonnei* Phase I lipopolysaccharide O-antigen, *Streptococcus pneumoniae* type 1 capsular polysaccharide, and *Streptococcus pneumoniae* group antigen C substance.

30 26. The method of claim 19, wherein the nutritional formula or nutritional supplement is a nutritional formula.

27. The method of claim 19, wherein the nutritional formula or nutritional supplement is a nutritional supplement.
- 5 28. The method of claim 19, wherein the enterally administering is orally administering.
29. The method of claim 19, wherein the infant is 0-6 months old.
- 10 30. The method of claim 19, wherein the immune system maturation is an increase in a T helper 1 marker to a T helper 2 marker.
31. The method of claim 30, wherein the T helper 1 marker is a cytokine selected from interferon gamma (IFN- γ) and interleukin 2 (IL-2).
- 15 32. The method of claim 30, wherein the T helper 2 marker is a cytokine selected from interleukin 4 (IL-4) and interleukin 5 (IL-5).

1/12




Fig. 1A




Fig. 1B




Fig. 1C

2/12




Fig. 1D




Fig. 1E

3/12




Fig. 2A




Fig. 2B




Fig. 2C

4/12




Fig. 3A




Fig. 3B

5/12




Fig. 3C




Fig. 3D

6/12




Fig. 4A




Fig. 4B

7/12




Fig. 4C

8/12




Fig. 5A




Fig. 5B

9/12




Fig. 5C




Fig. 5D

10/12




Fig. 6A




Fig. 6B

11/12




Fig. 6C




Fig. 6D

12/12

